Aoa dx is developing the next frontier in early-stage cancer detection for women through its pioneering work in glycolipids and proprietary biomarker technology. Our revolutionary tumor marker ganglioside platform, glycolocate™, is paving the way for life-saving early cancer detection. In a first of its kind, aoa dx is developing akrivis gd™, an early-stage liquid biopsy test for ovarian cancer, that has proven excellent sensitivity and specificity in a recent study. We foresee novel tumor biomarker gangliosides as the future for diagnosis, prognosis, monitoring, and eventually targeted therapies across multiple cancers. Aoa dx was co-founded by three experts and passionate advocates of women’s health, who have worked together at two previous diagnostic startups, that both resulted in successful exits upon commercialization. Aoa dx, a y combinator and vc backed company, raised an oversubscribed seed round to accelerate development and clinical studies. Awards & accelerators:
1.
